NCT00540618

A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis

A Phase II Randomized, Placebo-Controlled, Double-Blind Study of MEDI-507, A Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 420 (actual)
• Sponsor: MedImmune LLC · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To compare disease activity, as measured by PASI score, of three MEDI-507 dosing (injection)regimens vs. placebo.

Detailed description

The primary objective of this study is to compare disease activity, as measured by PASI score, of three MEDI-507 dosing regimens (5 mg for 12 weeks, 5 mg for 6 weeks, 7 mg for 4 weeks) versus placebo administered weekly by SC injection.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	MEDI-507	Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
OTHER	Placebo
DRUG	MEDI-507	Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
DRUG	MEDI-507	Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)

Timeline

• Start date: 2001-09-01
• Completion: 2003-07-01
• First posted: 2007-10-08
• Last updated: 2007-11-28

Locations

43 sites across 2 countries: United States, Canada